Elite Pharmaceuticals (ELTP)
(Delayed Data from OTC)
$0.49 USD
-0.02 (-4.78%)
Updated Aug 1, 2025 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ELTP 0.49 -0.02(-4.78%)
Will ELTP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELTP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELTP
The Zacks Analyst Blog Highlights Cisco Systems, Caterpillar, Charles Schwab and Elite Pharmaceuticals
Top Analyst Reports for Cisco, Caterpillar & Charles Schwab
ELTP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elite Pharmaceuticals Stock Dips Despite Record FY25 Revenue Jump
Zacks Market Edge Highlights: Elite Pharmaceuticals and Frequency Electronics
2 Defensive American Small Cap Stocks for 2025
Other News for ELTP
Elite Pharmaceuticals Inc (ELTP) Q4 2025 Earnings Call Highlights: Revenue Surge Amidst ...
Q4 2025 Elite Pharmaceuticals Inc Earnings Call Transcript
Elite Pharmaceuticals, Inc. (ELTP) Q4 2025 Earnings Call Transcript
Elite Pharmaceuticals (ELTP) Reports 48% Revenue Jump in Fiscal Year
Elite Pharmaceuticals reports FY results